ONCS News and Press, OncoSec Medical Incorporated From 01/19/21

OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™ Sirtex to Pay $5 Million for a Non-Exclusive Option to Co-Promote TAVO in Patients with Checkpoint Refractory Metastatic Melanoma in the U.S. and an Additional $25 Million if the Option is Exerci...

OncoSec Medical ([[ONCS]] +1.4%) announces that the first patient was dosed in its investigator-initiated OMS-104 Phase 2 trial evaluating Tavo (tavokinogene telseplasmid) in patients with operable, locally or regionally advanced melanoma, a type of skin cancer.The study aims to evaluate...

OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma PR Newswire PENNINGTON, N.J. and SAN DIEGO , Jan. 8, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or...

OncoSec Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO™ and Its Gene Electrotransfer Technology PENNINGTON, N.J. and SAN DIEGO , Dec. 10, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Comp...

OncoSec Announces Publication in International Journal of Surgery Case Reports PENNINGTON, N.J. and SAN DIEGO , Dec. 3, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company developi...

OncoSec Announces Exclusive License Agreement for Cliniporator® Gene Electrotransfer Platform Developed by IGEA Clinical Biophysics -- Agreement accelerates OncoSec's plan to treat visceral lesions in clinical trials with VLA -- -- Favorable licensing terms with broad f...

OncoSec Provides Highlights from Analyst & Investor Day and SITC 2020 and Announces KEYNOTE-695 Reaches Full Enrollment OncoSec Provides Highlights from Analyst & Investor Day and SITC 2020 and Announces KEYNOTE-695 Reaches Full Enrollment -- Significance of 30% over...

OncoSec has had very promising results in metastatic melanoma. It has also expanded its program in triple-negative breast cancer to now treat first-line patients. I review data from the melanoma program to help explain its significance. The stock is up on the news, but I belie...

Pfizer and BioNTech's announcement that, based on preliminary data, their COVID-19 vaccine is 90% effective and an emergency use authorization ((EUA)) is only weeks away has led to downward pressure on some of the second tier developers. If all goes according to plan, deployment could start b...

OncoSec Medical (ONCS) announces new positive interim data from its KEYNOTE-695 Phase 2b trial evaluating TAVO (tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (IL-12), in combination with Merck's (MRK) KEYTRUDA (pembrolizumab) in rigorously defined anti-PD1 checkpoint resistan...